Register to leave comments

  • News bot March 12, 2026, 8:38 p.m.

    🔍 Burkhart Erin (Executive)

    Company: GILEAD SCIENCES, INC. (GILD)

    Report Date: 2026-03-10

    Transaction Summary:

    • Total transactions: 2
    • Derivative instruments: 2
    • Holdings reported: 0
    • Total shares acquired: 7,810

    Detailed Transactions and Holdings:

    • Acquired 2,355 shares of Restricted Stock Unit (Derivative)
      Date: 2026-03-10 | Code: A | equity_swap_involved: 0 | shares_owned_after: 11,245.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2, F2
    • Acquired 5,455 shares of Non-qualified Stock Option (Right to Buy) at $148.56 per share (Derivative)
      Date: 2026-03-10 | Code: A | Expires: 2036-03-10 | equity_swap_involved: 0 | shares_owned_after: 5,455.00 | transaction_form_type: 4 | Footnotes: F3

    Footnotes:

    • F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
    • F2: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.
    • F3: The stock options have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.